Tags: Allergies | dupilumab | asthma | eczema | treatment | drug

Asthma, Eczema Sufferers Get Dramatic Relief From New Allergy Drug

Friday, 19 Sep 2014 04:28 PM

Regeneron Pharmaceuticals Inc has quickly become one of the world's biggest biotech companies thanks to its Eylea treatment for macular degeneration, but its little known experimental allergy drug could become equally successful, senior company executives said in interviews.

The allergy drug, dupilumab, is meant to treat underlying causes of asthma, eczema and nasal polyps and could transform treatment of those suspected related ailments, the officials say.

"We have a lot of debate within the company as to which of our many programs is the most exciting, and a lot of people are voting on dupilumab," Regeneron research chief George Yancopoulos said in an interview at company headquarters.
 
 
 
 
The other contender is a new type of cholesterol treatment, called alirocumab, which Regeneron expects to submit for regulatory approval later this year.
 
Dupilumab works by blocking IL-4 and IL-13, two immune system proteins that attack healthy tissue and cause inflammation in different parts of the body. The medicine, co-developed with French drugmaker Sanofi, slashed asthma flareups by 87 percent in a mid-stage trial described last year.
 
A measurement of eczema symptoms and surface area involvement diminished by 45 to 74 percent in a separate mid-stage trial of dupilumab described in July. It involved patients with moderate to severe atopic dermatitis, a chronic type of eczema.
 
Data from mid-stage trials of the drug against nasal polyps - growths that impair smell, breathing and sleeping and which are linked to sinus infections - are expected in coming months and could give a fuller portrait of dupilumab's potential.
 
"If dupilumab is equally impressive against nasal polyps, I think it will nail the hypothesis that this spectrum of allergic diseases are all inter-related variations of the same disease" and due to the inflammation-causing proteins, Yancopoulos said.

Millions of people worldwide suffer from various combinations of asthma, nasal polyps and atopic dermatitis, pointing to potential high demand for dupilumab, Yancopoulos said.
 

Michael Aberman, head of business development at Regeneron, said dupilumab may have great potential if it performs well in ongoing late-stage studies and is approved.

"We believe we're getting at the crux of all these diseases" linked to allergies, he said.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Health-News
Regeneron Pharmaceuticals Inc has quickly become one of the world's biggest biotech companies thanks to its Eylea treatment for macular degeneration, but its little known experimental allergy drug could become equally successful, senior company executives said in interviews.The...
dupilumab, asthma, eczema, treatment, drug
355
2014-28-19
Friday, 19 Sep 2014 04:28 PM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved